glp-1 kidney Glucagon-like peptide-1 receptor agonists in diabetic disease: A review of their kidney and heart protection GLP-1 RAs Show Renal, Survival

Research into sublingual semaglutide is still ongoing, but initial studies have shown positive results

A dose taken with imperfect timing is always better than a dose not taken at all

Sebzda, E., Bracke, M., Tugal, T., Hogg, N

If semaglutide gets approved, it could give us doctors another way to help millions of people

For individuals significantly above 250 pounds, extended protocols of 16-20 weeks rather than higher daily doses often produce better outcomes

IPaT focuses on real-world impact, translating research out of the lab and into peoples lives in the form of real products, applications, and community education and programming